China Launches Clinical Evidence-Based Intelligence Capacity Building Initiative at ZGC Forum

Stock News
03/26

On March 26, the "World Digital Health Forum" held during the 2024 ZGC Forum Annual Conference unveiled a series of "Medical Technology Innovation Achievements." Among these, the "China Clinical Evidence-Based Intelligence Capacity Building Plan" was officially launched as a major initiative. This represents the first industry-wide collaborative effort in China focused on the deep integration of evidence-based medicine and artificial intelligence. The plan was jointly initiated by several prominent domestic medical institutions, including Beijing Tsinghua Changgung Hospital affiliated with Tsinghua University, with core AI capabilities provided by leading AI healthcare company YIDU TECH (02158).

The central technological platform for this initiative, the clinical evidence-based intelligence platform named "Yidu Smart循" APP, was simultaneously released and made available for use by physicians. The forum gathered numerous distinguished domestic and international guests, including Chinese Academy of Engineering President Li Xiaohong, Brunei's Minister of Health Mohammad Isham Jaafar, Indonesian Minister of Health Budi Gunadi Sadikin, Beijing Vice Mayor Jin Wei, and Tsinghua University Vice President Wang Hongwei, who delivered addresses. The conference was chaired by Dong Jiahong, Academician of the Chinese Academy of Engineering, Dean of Tsinghua University Clinical Medical School, and President of Beijing Tsinghua Changgung Hospital.

**Leading Hospitals and Industry Collaboration Address Clinical Needs** Currently, a new medical research paper is published globally every 30 seconds, and clinical guidelines are frequently updated. However, the efficiency for frontline clinicians to access and apply high-quality evidence-based information remains insufficient—a contradiction particularly acute within tiered healthcare systems. The newly launched plan is designed specifically to address this structural challenge. Relying on a multi-center clinical expert collaboration mechanism, it systematically integrates real-world medical evidence, domestic and international clinical guidelines, and cutting-edge research findings. The objective is to build a practical, evidence-based intelligence capacity system tailored to China's clinical realities that can be effectively implemented and promoted. Medical institutions, including Beijing Tsinghua Changgung Hospital, are deeply involved, forming a closed-loop collaboration from specialized knowledge validation to clinical scenario adaptation.

As a core participant, YIDU TECH is responsible for underlying knowledge modeling and AI capability output, with the "Yidu Smart循" platform serving as the primary technological vehicle and product. Previously, YIDU TECH's AI solutions have undergone long-term clinical practice in institutions such as Peking Union Medical College Hospital, Sun Yat-sen University Cancer Center, and Peking University Cancer Hospital, accumulating comprehensive experience spanning from data governance to intelligence agent development. Through this industry collaborative plan, YIDU TECH aims to extend its intelligent evidence-based capabilities to broader scenarios, enabling more physicians to conveniently access high-quality evidence-based support.

**Triple-Role Strategy: Yidu Smart循 Redefines Evidence-Based Decision-Making Value** According to Xu Jiming, Co-founder and CEO of YIDU TECH, Yidu Smart循 moves beyond the limitations of traditional "information retrieval tools." With a clear positioning as a "super assistant, second brain, and multi-disciplinary intelligent expert consultant team," it aims to become a core support system for physicians' clinical work.

1. **Clinical "Super Assistant": Efficient Workload Reduction and Personalized Adaptation** For physicians, Yidu Smart循 acts as a "super assistant" that balances efficiency with personalization. It has built an evidence-based knowledge base covering over 30,000 authoritative clinical guidelines and more than 5 million selected medical literature articles. Collaborating with organizations like People's Medical Publishing House, it has established a standardized knowledge system and tracks updates from globally authoritative journals in real-time. Whether for outpatient prescriptions, ward round decisions, or case discussions, physicians can input a clinical question and receive precise conclusions within seconds. Furthermore, the "Personal Knowledge Base" function allows doctors to save and upload approved guidelines and literature, organizing and querying them according to personal habits, effectively creating a personalized knowledge space akin to a "mobile study."

2. **Decision-Making "Second Brain": Traceable Sources for Enhanced Medical Safety** Clinical decision-making demands absolute clarity. Yidu Smart循 adheres to a "traceable to the source" principle, where every conclusion is accompanied by an "evidence ID" supporting one-click access to the original text. It also employs the international GRADE evidence grading system to assess the quality of retrieved evidence and incorporates multiple verification mechanisms to automatically check literature support, filtering out unsubstantiated conclusions. This systematically reduces the risk of "AI hallucination" from a technical standpoint. This fully transparent and verifiable decision-making logic functions like a "second brain" for doctors, compensating for the limits of human memory while providing rigorous evidence support, thereby making each decision more secure and reliable.

3. **N "Expert Consultant Teams": Specialized Depth for Diverse Clinical Needs** The multi-specialty and multi-scenario nature of clinical diagnosis and treatment means general-purpose AI often falls short in specialized areas. Yidu Smart循 innovatively constructs a "multi-specialty intelligent agent collaboration engine," effectively forming N "expert consultant teams" for physicians. The system can automatically identify the specialty attributes and clinical intent of a query and precisely route it to the corresponding specialized intelligent agent for processing. These agents are developed through deep refinement within hospital settings: YIDU TECH has cultivated over 200 specialized agents trained on domain-specific data and thoroughly validated in real clinical environments across partner hospitals. This collaborative effort from specialized "consultant teams" addresses the weakness of general AI being "broad but not deep," offering decision support that aligns more closely with actual diagnostic and treatment logic.

**Expanding Access and Deepening Hospital Integration** Addressing the in-depth needs of medical institutions, Yidu Smart循 also offers a hospital-specific version. This version can flexibly adjust the weighting of specialty agents based on a hospital's disciplinary strengths, precisely adapt to internal drug formularies, treatment protocols, and quality control requirements, and supports collaborative building of customized knowledge bases with hospital experts. Crucially, this version can achieve deep integration with existing hospital information systems like HIS and EMR, enabling seamless linkage between patient data and the evidence-based knowledge base. This integration allows intelligent evidence-based decision support to become truly embedded within clinical workflows.

From an "information tool" to a "decision-making basis entry point," from "generalized AI" to "specialty-level intelligence," from "passive querying" to "active workflow integration"—Yidu Smart循 is redefining the value boundaries of AI in healthcare. The "China Clinical Evidence-Based Intelligence Capacity Building Plan" launched at the ZGC Forum marks not only the beginning of industry collaboration but also a significant step towards intelligent and accessible "evidence-driven decision-making" in Chinese healthcare. The vision is to ground clinical decisions firmly in evidence, ensuring every recommendation is well-supported. Yidu Smart循 is turning this vision into reality.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10